FMP
XOMA Corporation
XOMA
NASDAQ
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
19.72 USD
-0.47 (-2.38%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
29.39M
38.16M
6.03M
4.76M
28.49M
30.24M
32.1M
34.07M
36.17M
38.39M
Revenue %
-
29.86
-84.21
-21.06
498.72
6.15
6.15
6.15
6.15
Ebitda
13.81M
16.52M
-16.84M
-39.36M
-5.42M
-7.79M
-8.27M
-8.77M
-9.31M
-9.89M
Ebitda %
47.01
43.28
-279.49
-827.28
-19.04
-25.75
-25.75
-25.75
-25.75
Ebit
13.64M
16.35M
-17.12M
-40.26M
-5.64M
-7.89M
-8.38M
-8.89M
-9.44M
-10.02M
Ebit %
46.42
42.85
-284.04
-846.2
-19.79
-26.11
-26.11
-26.11
-26.11
Depreciation
172k
167k
274k
900k
216k
1.53M
1.62M
1.72M
1.83M
1.94M
Depreciation %
0.59
0.44
4.55
18.92
0.76
5.05
5.05
5.05
5.05
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
84.22M
94.1M
58.16M
153.45M
105.18M
30.24M
32.1M
34.07M
36.17M
38.39M
Total Cash %
286.62
246.6
965.01
3.23k
369.23
100
100
100
100
Receivables
1.79M
209k
2.37M
15.22M
17.02M
12.44M
13.2M
14.01M
14.88M
15.79M
Receivables %
6.09
0.55
39.27
319.86
59.73
41.13
41.13
41.13
41.13
Inventories
1.61M
2.05M
1
-
-
656.3k
696.67k
739.51k
784.99k
833.27k
Inventories %
5.48
5.37
0
-
-
2.17
2.17
2.17
2.17
Payable
456k
1.07M
524k
653k
1.05M
1.84M
1.96M
2.08M
2.2M
2.34M
Payable %
1.55
2.81
8.69
13.72
3.7
6.1
6.1
6.1
6.1
Cap Ex
-1.21M
-26.5M
-23.25M
-17k
-20k
-10.52M
-11.17M
-11.86M
-12.59M
-13.36M
Cap Ex %
-4.11
-69.44
-385.71
-0.36
-0.07
-34.8
-34.8
-34.8
-34.8
Weighted Average Cost Of Capital
Price
19.72
Beta
Diluted Shares Outstanding
11.7M
Costof Debt
11.61
Tax Rate
After Tax Cost Of Debt
8.24
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
119.2M
Total Equity
230.74M
Total Capital
349.94M
Debt Weighting
34.06
Equity Weighting
65.94
Wacc
9.51
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
29.39M
38.16M
6.03M
4.76M
28.49M
30.24M
32.1M
34.07M
36.17M
38.39M
Ebitda
13.81M
16.52M
-16.84M
-39.36M
-5.42M
-7.79M
-8.27M
-8.77M
-9.31M
-9.89M
Ebit
13.64M
16.35M
-17.12M
-40.26M
-5.64M
-7.89M
-8.38M
-8.89M
-9.44M
-10.02M
Tax Rate
29.05
29.05
29.05
29.05
29.05
29.05
29.05
29.05
29.05
29.05
Ebiat
15.38M
16.26M
-17.1M
-40.26M
-4M
-7.43M
-7.88M
-8.37M
-8.88M
-9.43M
Depreciation
172k
167k
274k
900k
216k
1.53M
1.62M
1.72M
1.83M
1.94M
Receivables
1.79M
209k
2.37M
15.22M
17.02M
12.44M
13.2M
14.01M
14.88M
15.79M
Inventories
1.61M
2.05M
1
-
-
656.3k
696.67k
739.51k
784.99k
833.27k
Payable
456k
1.07M
524k
653k
1.05M
1.84M
1.96M
2.08M
2.2M
2.34M
Cap Ex
-1.21M
-26.5M
-23.25M
-17k
-20k
-10.52M
-11.17M
-11.86M
-12.59M
-13.36M
Ufcf
11.4M
-8.32M
-40.73M
-52.1M
-5.2M
-11.71M
-18.12M
-19.24M
-20.42M
-21.68M
Wacc
9.51
9.51
9.51
9.51
9.51
Pv Ufcf
-10.69M
-15.11M
-14.65M
-14.2M
-13.76M
Sum Pv Ufcf
-68.41M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.51
Free Cash Flow T1
-22.11M
Terminal Value
-294.31M
Present Terminal Value
-186.85M
Intrinsic Value
Enterprise Value
-255.26M
Net Debt
17.54M
Equity Value
-272.8M
Diluted Shares Outstanding
11.7M
Equity Value Per Share
-23.31
Projected DCF
-23.31 1.846%
